Zelira Therapeutics Ltd's (ASX:ZLD) (OTCQB:ZLDAF) (FRA:G1G) Harry Karelis and Dr Oludare Odumosu speak to Proactive's Andrew Scott soon after announcing record product sales and licensing revenues of A$225,000 during the March quarter - up 249% on the prior six months. They say the revenue growth demonstrates the start of the company’s commercialisation ramp-up, with growth driven largely by the successful December 2020 launch of the Sprinjene CBD oral care product in the USA.
Zelira Therapeutics well positioned for 'multiple product launches in 2021'
